Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Editorial Volume 3 Issue 4

Promising Drug Candidates for 2019-Novel Coronavirus (COVID-19) Pneumonia and Related Acute Respiratory Syndrome Treatment

Attapon Cheepsattayakorn1* and Ruangrong Cheepsattayakorn2

110th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
2Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: February 18, 2020; Published: March 01, 2020


  Patients with 2019-nCoV (COVID-19) infection are being recruited in randomized clinical trials to evaluate the efficacy of favipiravir plus phase III clinical trial were began in early February 2020 to evaluate intravenous remedesivir (200 mg on day 1 and 100 mg once daily for 9 days) in 2019-nCoV (COVID-19)-infected patients (NCT04252664 and NCT04257656), with estimated completion dates in April 2020. Favipiravir (T-705), an approved guanine analogue with effective inhibition of the RNA-dependent RNA polymerase of RNA viruses was reported recently against 2019-nCoV (COVID-19) (EC50 = 61.88 µM in Vero E6 cells). Other approved nucleoside analogues (ribavirin) and experimental nucleoside analogue (galidesivir) may have potential against 2019-nCoV (COVID-19). Nucleoside analogues in the form of adenine or guanine derivatives target the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronavirus.

  HIV protease inhibitors (lopinavir and ritonavir) have been initiated to test in 2019-nCoV (COVID-19)-infected patients in clinical trials (ChiCTR2000029539, etc.). Lopinavir and ritonavir appeared to be associated with improved clinical outcomes of SARS and MERS patients in a non-randomized open-label trial by hypothesized inhibition of the 3-chymotrypsin-like protease of SARS and MERS. Nevertheless, it is questionable whether HIV protease inhibitors could effectively inhibit the papain-like and 3-chymotrypsin-like proteases of 2019-nCoV (COVID-19). Griffithsin, a red-alga-derived lectin (spike glycoprotein) is also a promising target against 2019-nCoV (COVID-19). Subcutaneous interferon therapies should be closely monitored and dose reduction or discontinuation of therapy may be needed due to its multiple adverse effects. Nitazoxanide could also inhibit 2019-nCoV (COVID-19) (EC50 = 2.12 µM in Vero E6 cells). Chloroquine, an approved immune modulator demonstrates inhibitory effects against 2019-nCoV (COVID-19) (EC50 = 1.13 µM in Vero E6 cells). Small-molecule agents may also modulate the virus-host interactions of 2019-nCoV (COVID-19).





Citation: Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn. “Promising Drug Candidates for 2019-Novel Coronavirus (COVID-19) Pneumonia and Related Acute Respiratory Syndrome Treatment". Acta Scientific Microbiology 3.4 (2020): 01.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US